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eutrophils must follow both endogenous and bacterial
chemoattractant signals out of the vasculature and
through the interstitium to arrive at a site of infec-
tion. By necessity, in the setting of multiple chemoattrac-
tants, the neutrophils must prioritize, favoring end target
chemoattractants (e.g., fMLP and C5a) emanating from the
site of infection over intermediary endogenous chemoattrac-
tants (e.g., IL-8 and LTB
 
4
 
) encountered en route to sites of
infection. In this study, we propose a hierarchical model of
two signaling pathways mediating the decision-making
process of the neutrophils, which allows end target molecules
to dominate over intermediary chemoattractants. In an under
agarose assay, neutrophils predominantly migrated toward
end target chemoattractants via p38 MAPK, whereas inter-
mediary chemoattractant-induced migration was phos-
phoinositide 3-kinase (PI3K)/Akt dependent. When faced
with competing gradients of end target and intermediary
chemoattractants, Akt activation was signiﬁcantly reduced
within neutrophils, and the cells migrated preferentially
N
 
toward end target chemoattractants even at 1/1,000th that
of intermediary chemoattractants. End target molecules did
not require chemotactic properties, since the p38 MAPK
activator, LPS, also inhibited Akt and prevented migration
to intermediary chemoattractants. p38 MAPK inhibitors not
only reversed this hierarchy, such that neutrophils migrated
preferentially toward intermediary chemoattractants, but
also allowed neutrophils to be drawn out of a local end target
chemoattractant environment and toward intermediary
chemoattractants unexpectedly in an exaggerated (two- to
ﬁvefold) fashion. This was entirely related to signiﬁcantly
increased magnitude and duration of Akt activation. Finally,
end target chemoattractant responses were predominantly
Mac-1 dependent, whereas nondominant chemoattractants
used primarily LFA-1. These data provide support for a two
pathway signaling model wherein the end target chemo-
attractants activate p38 MAPK, which inhibits intermediary
chemoattractant-induced PI3K/Akt pathway, establishing
an intracellular signaling hierarchy.
 
Introduction
 
Neutrophils constitute the first line of defense against infectious
agents and therefore play a central role in the inflammatory
response. Upon infection and/or tissue damage, the neutrophils
must first adhere to endothelium in response to chemokines
presented at the endothelial interface and then migrate out
of the microvasculature by following other chemokines secreted
from nearby macrophages, mast cells, and other serosal cells
(for review see Luster, 1998). These chemokines allow neutro-
phils to arrive in the general vicinity of the infection and
would by definition have an intermediary role. Once in the
vicinity, the neutrophils would then follow a series of end
target chemoattractants including bacterial products and
complement fragments to the final site of infection. Clearly,
there are many chemoattractants that neutrophils encounter en
route, and mechanisms must be in place for the cell to integrate
and prioritize all of the multiple directional cues. Therefore,
it would seem reasonable that a hierarchy of chemokines
would exist, with some molecules being clearly dominant
over others. Indeed, numerous investigators have demonstrated
preferential migration toward end target chemoattractants,
including fMLP and C5a, despite the presence of high con-
centrations of host-derived (intermediary) chemoattractants
such as IL-8 or LTB
 
4
 
 (Campbell et al., 1997; Foxman et al.,
1997, 1999; Shen et al., 2000). These data have led us to
hypothesize that an intracellular signaling hierarchy also exists
in the neutrophil decision-making process.
Despite the profound structural differences between the
many chemoattractants, the receptors for these molecules are
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similar in that they belong to the seven-transmembrane helix
receptor family (Damaj et al., 1996; Prossnitz et al., 1999).
Once activated, these receptors transmit their signals to het-
erotrimeric G proteins, which activate downstream path-
ways leading to rapid cytoskeletal rearrangements and che-
motaxis (Amatruda et al., 1995; Schraufstatter et al., 2001).
Phosphoinositide 3-kinase (PI3K)* appears to be a key mol-
ecule in one of the intracellular pathways of neutrophil che-
motaxis (Hirsch et al., 2000). Although multiple PI3K iso-
forms exist, chemotactic receptors utilize the p110
 
 
 
 catalytic
isoform, which is responsible for downstream events in-
cluding the conversion of membrane phospholipid phos-
phatidylinositol 4,5-biphosphate into phosphatidylinositol
3,4,5-triphosphate. This leads to the phosphorylation and
activation of protein kinase B (also known as PKB or Akt).
This is best evidenced by the fact that activation of chemo-
tactic receptors in mice lacking p110
 
 
 
 manifests as no phos-
phorylation or no activation of PKB/Akt, leading to defects
in chemotaxis (Hirsch et al., 2000).
However, P110
 
 
 
-deficient neutrophils can still chemotax
in significant numbers (Hirsch et al., 2000). Indeed, the p38
MAPK pathway has also been demonstrated to play a very
important role in neutrophil chemotaxis in humans (Nick et
al., 1997) and mice (Cara et al., 2001), and this pathway is
still effectively activated in p110
 
 
 
-deficient cells, perhaps ex-
plaining neutrophil recruitment to sites of inflammation in
these mice (Sasaki et al., 2000). Whether the p38 MAPK
and PI3K/Akt pathways are complementary, overlapping, or
perhaps even opposing and whether they function in a hier-
archical fashion remains unclear. Furthermore, whether
there is any physiologic cross-talk between these pathways
has never been addressed.
In this study, our data would support the proposed model
that end target chemoattractants (fMLP and C5a) function
primarily by stimulating p38 MAPK, whereas intermediary
chemoattractants (IL-8 and LTB
 
4
 
) primarily function via the
PI3K/Akt pathway. These pathways underlie the hierarchi-
cal dominance of end target chemoattractants over interme-
diary chemoattractants inasmuch as activation of the p38
MAPK pathway in neutrophils inhibits the PI3K/Akt path-
way. Tonic inhibition of PI3K/Akt is apparent, since inhibi-
tion of p38 MAPK causes a marked increase in PI3K/Akt
activity and a causally related exaggerated chemotactic re-
sponse to intermediary chemokines.
 
Results
 
Dose response for IL-8 and fMLP
 
Fig. 1 a summarizes how chemotaxis was determined, and
Fig. 1 b shows the under agarose design for the dose re-
sponse experiments. Neutrophils were placed in two wells
equidistant from a middle well that was the source of the
chemoattractant. Neutrophils moved equally toward the
central well from the left and the right well, suggesting that
the chemoattractants diffused equally in both directions. We
found that neutrophils migrate at concentrations between
0.1 and 10.0 pmol, with higher concentrations resulting in
stasis and lower concentrations having no effect (Fig. 1 c).
The optimal concentration of fMLP for neutrophil chemo-
taxis was found to be 1.0 pmol. At every concentration used,
directional migration was observed in that 99% of neutro-
phils migrated toward (rather than away from) the source of
chemoattractant and only one or two cells were seen moving
in the opposite direction. The distance of neutrophil chemo-
taxis to fMLP followed an identical trend and was optimal at
1.0 pmol (unpublished data). At this concentration, neutro-
phils migrated 2,000 
 
 
 
m in 2 h or 
 
 
 
15–20 
 
 
 
m/min. IL-8
produced a similar bell-shaped response curve for both the
number of migrating cells and the distance traveled, with the
optimal IL-8 dose seen at 10.0 pmol (unpublished data). In
all of the following experiments, inhibitors caused a very
similar decrease in the number of migrating cells, the dis-
tance traveled, and the migratory rate; therefore, only the
number of cells is presented.
 
Effects of p38 MAPK and PI3K Inhibition on migration 
toward end target and intermediary chemoattractants
 
Two p38 MAPK inhibitors (SKF86002 and SB203858) and
two PI3K inhibitors (wortmannin and LY294002) were
used to determine which chemoattractants induce chemo-
taxis via the p38 MAPK and PI3K pathways. All inhibitors
were used at optimal concentrations based on very extensive
characterization by other groups (Zu et al., 1998) and by
confirmation of these results in our own preliminary experi-
 
*Abbreviation used in this paper: PI3K, phosphoinositide 3-kinase.
Figure 1. Gel setup and analysis. (a) Target areas used to measure 
chemotaxis. Randomly migrating neutrophils will appear in equal 
numbers in both target areas. Directionally migrating neutrophils 
will only be found in target area A. The number of chemotaxis cells 
can be determined by subtracting the number of cells in area B from 
the number of cells in area A. (b) Under agarose setup used for dose 
response experiments. (c) fMLP dose response. Data is shown as 
mean   SEM (n   8). *P   0.05 compared with 0.0 pmol fMLP. 
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ments. Fig. 2 a illustrates that neutrophil migration to 1.0
pmol of the end target chemoattractant fMLP was inhibited
by 
 
 
 
90% by both p38 MAPK inhibitors. Similarly, C5a-
induced neutrophil migration was also inhibited completed
by SB203580. In contrast, the PI3K inhibitors decreased mi-
gration to a much lesser degree in response to fMLP (35%)
and by even less in response to C5a (Fig. 2 b). Treating the
neutrophils with both a p38 MAPK inhibitor (SB203850)
and a PI3K inhibitor (LY294002) inhibited chemotaxis
as effectively as a p38 MAPK inhibitor alone (unpub-
lished data). Clearly, the end target chemoattractants signal
through a p38 MAPK–dominated pathway in which PI3K
plays only a very minor role.
Fig. 2 a also shows the effects of the p38 MAPK inhibi-
tors on neutrophil migration to 10.0 pmol of the intermedi-
ary chemoattractant, IL-8. The p38 MAPK inhibitor
SKF86002 had no effect on the ability of neutrophils to
chemotax to IL-8. The p38 MAPK inhibitor SB203850 had
a minor effect on chemotaxis to IL-8; a 35% decrease was
noted. A similar 30–40% decrease with SB203850 in che-
motaxis was noted in response to LTB
 
4
 
. In complete con-
trast, both of the PI3K inhibitors dramatically decreased
migration to IL-8, with wortmannin blocking 88% of che-
motaxis and LY294002 blocking 78% of chemotaxis to IL-8
(Fig. 2 b). Similarly, LY294002 inhibited 
 
 
 
90% of the che-
motaxis in response to the intermediary chemoattractant
LTB
 
4
 
. Treating neutrophils with both a p38 MAPK inhibi-
tor (SB203850) and a PI3K inhibitor (LY294002) decreased
chemotaxis as effectively as a PI3K inhibitor alone (unpub-
lished data). These data suggest that the intermediary
chemoattractants signal through a PI3K-dominated pathway
in which p38 MAPK may play only a very minor role.
 
Competing gradients of end target 
and intermediary chemoattractants
 
In competing gradients consisting of optimal concentra-
tions of fMLP (1 pmol; in right well) and 1/100th optimal
concentration of IL-8 (0.1 pmol; in left well), neutrophils
preferentially migrated toward fMLP (Fig. 3 a). When opti-
mal concentrations of both fMLP and IL-8 were added,
neutrophils still migrated toward fMLP, unexpectedly in
much greater numbers. This pattern was repeated with
competing gradients consisting of 1/100th optimal concen-
tration of fMLP (0.01 pmol) and optimal concentrations of
IL-8 (10.0 pmol). Under these conditions, neutrophils still
preferentially migrated toward fMLP, although the effect
was less pronounced (Fig. 3 a). It is noteworthy that this
lower concentration of fMLP (without IL-8 present) does
not induce any migration (Fig. 1 c), suggesting that not
only does fMLP overcome any effects of IL-8, but the cells
migrate more effectively in the presence of the opposing
IL-8 gradient. Neutrophils also migrated toward fMLP in
an opposing LTB
 
4
 
 gradient (Fig. 3 a). The other end target
chemoattractant, C5a, induced neutrophil chemotaxis in a
dominant fashion over optimal doses of LTB
 
4
 
 or IL-8 (Fig.
3 a). When opposing gradients of two end target chemoat-
tractants (fMLP versus C5a) were used, there was no domi-
nance for either chemoattractant, since neutrophils mi-
grated equally well in both directions (unpublished data),
consistent with the same rather than different signaling
pathways being involved. An identical response was ob-
served when the opposing gradients of the two intermediary
chemoattractants (LTB
 
4
 
 versus IL-8) were used (unpub-
lished data). For the remainder of the experiments, fMLP
and IL-8 are used to further explore the mechanisms of ac-
tion. Nevertheless, in numerous instances similar results are
observed for C5a and LTB
 
4
 
.
fMLP is a smaller molecule then IL-8 (3 amino acids versus
88 amino acids), and therefore, the hierarchy may have been
a result of faster diffusion of fMLP than IL-8. To show that
this hierarchy was not a result of different diffusion rates, we
used gels containing two wells; neutrophils and IL-8 were
loaded into one well, and fMLP was loaded into a second dis-
tal well. Despite this very high local concentration of IL-8,
Figure 2. Effect of p38 MAPK and PI3K in neutrophil chemotaxis from the left well to the right well in response to fMLP, IL-8, C5a, and 
LTB4. Neutrophils were pretreated for 60 min with either 30  M SKF86002, 10  M SB203850, 100 nM wortmannin, or 50  M LY294002. 
UT, untreated neutrophils. (a) Effect of the p38 MAPK inhibitors on neutrophil chemotaxis. (b) Effect of the PI3K inhibitors on chemotaxis. 
Data is shown as mean   SEM with a minimum of n   8 for each experiment. *P   0.05 compared with UT. 
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neutrophils migrated to fMLP (Fig. 3 b). Once again, fMLP
(10.0 pmol) induced twice the number of neutrophils to mi-
grate out of the local IL-8 gradient then is observed without
IL-8 (Fig. 1 c). fMLP receptor numbers were measured in the
presence and absence of IL-8, and a 60% increase in fMLP
receptor number was consistently noted (Table I).
We then reversed the positions of the chemoattractants
(neutrophils and fMLP in one well and IL-8 into the second
well). Under these conditions, neutrophils remained in the
fMLP-containing well and did not migrate to IL-8 (Fig. 3
b). These results suggest that regardless of the concentrations
of fMLP and IL-8 or the diffusion distance, neutrophils al-
ways prefer the end target chemokine fMLP.
 
Changes in downstream events of the IL-8 receptors 
mediates the chemotactic hierarchy
 
To determine why end target molecules dominated over in-
termediary chemoattractants, we next examined whether
fMLP directly affects IL-8 receptor number and/or down-
stream events. Fig. 4 a illustrates that fMLP had absolutely
no effect upon either CXCR1 or CXCR2 (the two known
IL-8 receptors) at a wide range of concentrations. As a posi-
tive control, we show that CXCR1 and CXCR2 were both
internalized in response to IL-8 (Fig. 4 a). Clearly, fMLP
does not affect IL-8 receptor numbers.
Since PI3K inhibition reduced IL-8 chemotaxis, we ex-
amined whether this pathway was affected by fMLP. To do
this, we measured the phosphorylation of the downstream
Figure 3. Neutrophils respond in a hierarchal manner to competing gradients of chemoattractants. (a) Migration of neutrophils in competing 
chemotactic gradients. Six gradients were tested: the first consisted of optimal fMLP (1.0 pmol) and 1/100th optimal IL-8 (0.1 pmol), the second 
consisted of 1/100th optimal fMLP (0.01 pmol) and optimal IL-8 (10.0 pmol), and the third consisted of optimal gradients of fMLP and IL-8. 
The fourth gradient consisted of optimal IL-8 and optimal C5a (10.0 pmol). The fifth gradient consisted of optimal LTB4 (10.0 pmol) and optimal 
fMLP. The final gradient consisted of optimal LTB4 and optimal C5a. (b) Migration of p38 MAPK inhibited neutrophils from a well containing 
10.0 pmol IL-8 or 1.0 pmol fMLP to wells containing various concentrations of fMLP or IL-8. Results are shown as mean   SE (n   10). 
*P   0.05 compared with migration toward fMLP.
 
Table I. 
 
Up-regulation of formyl-peptide receptor in response to 
IL-8 stimulation
IL-8 Increase in surface fPR
 
nM %
 
0 0.0 
 
 
 
 8.93
10 20.19 
 
 
 
 12.49
 
a
 
100 58.44 
 
 
 
 21.35
 
a
a
 
P 
 
 
 
 0.05 compared to 0 nM IL-8.
Results are shown as the percentage of increase in fluorescence 
 
 
 
 SEM.
Figure 4. Internalization and signaling of CXCR1 and CXCR2. 
(a) Internalization of CXCR1 and CXCR2 in response to 100 nM 
fMLP and/or 100 nM IL-8 (n   5). (b) Akt phosphorylation induced 
by 100 nM IL-8 (left) or 100 nM fMLP   100 nM IL-8 (right). Results 
are shown as mean   SEM (n   4). 
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molecule Akt as an index of PI3K activity. Akt has been
shown to be involved in the IL-8-induced PI3K activation
as much as mice deficient in the P110
 
 
 
 catalytic isoform
have no Akt phosphorylation. To confirm these findings in
our human system, we determined that the PI3K inhibitor
LY294002 prevented Akt phosphorylation in response to
IL-8 (unpublished data). Fig. 4 b summarizes that Akt
phosphorylation in response to IL-8 can be detected within
30 s, peaks within the first minute, and largely dissipates by
30 min. When neutrophils were stimulated with both
fMLP and IL-8, the Akt phosphorylation at peak levels is
less than half that seen with IL-8 alone and returns to con-
trol values by 5 min (Fig. 4 b). Together, these data suggest
that fMLP has a direct inhibitory effect upon the PI3K/Akt
pathway (Fig. 4 b) that is independent of IL-8 receptor
number (Fig. 4 a).
 
Effect of PI3K or p38 MAPK inhibition 
on the fMLP/IL-8 hierarchy
 
We looked at the effect of PI3K inhibition on the fMLP/IL-8
hierarchy. Two gradients were tested: the first consisting
of optimal fMLP (1.0 pmol) and 1/100th optimal IL-8 (0.1
pmol), and the second consisting of 1/100th optimal fMLP
(0.01 pmol) and optimal IL-8 (10.0 pmol). In both gradi-
ents, neutrophils treated with the PI3K inhibitor LY294002
still preferentially migrated toward fMLP (Fig. 5 a).
By contrast, p38 MAPK inhibition not only blocked the
preferential migration of neutrophils toward fMLP but also
reversed and greatly enhanced migration of neutrophils to-
ward IL-8. Indeed Fig. 5 b shows that when p38 MAPK–
treated neutrophils were placed in competing gradients
containing 1/100th optimal concentrations of fMLP (0.01
pmol) and optimal IL-8 concentrations (10.0 pmol), neutro-
phils preferentially migrated toward IL-8. Even more striking
was the fact that even when the conditions were greatly bi-
ased toward fMLP, i.e., when optimal concentrations of
fMLP (1.0 pmol) and 1/100th optimal concentrations of
IL-8 (0.1 pmol) were used, p38 MAPK–treated neutrophils
preferentially migrated toward IL-8. Similarly, when optimal
concentrations of fMLP and LTB
 
4
 
 were tested, p38 MAPK–
inhibited neutrophils migrated toward LTB
 
4
 
. Also shown in
Fig. 5 b is the fact that the number of neutrophils that mi-
grated toward IL-8 were approximately five times that nor-
mally seen in the absence of the opposing fMLP gradient.
The enhanced migration to IL-8 occurs only in the presence
of the p38 MAPK inhibitor and fMLP and not in the pres-
ence of the p38 MAPK inhibitor alone. This was not particu-
lar to this set of chemoattractants, since p38-inhibited neu-
trophils migrated in greater numbers to LTB
 
4
 
 in the presence
of an opposing fMLP gradient. Clearly, when p38 MAPK is
inhibited fMLP either activates additional pathways or in-
creases PI3K/Akt to enhance migration toward IL-8.
Figure 5. Migration of inhibitor-treated neutrophils in competing 
chemoattractant gradients. Five gradients were tested: the first 
consisted of optimal fMLP (1.0 pmol) and 1/100th optimal IL-8 
(0.1 pmol) and the second consisted of 1/100th optimal fMLP 
(0.01 pmol) and optimal IL-8 (10.0 pmol). (a) Migration of PI3K 
inhibited neutrophils. (b) Migration of p38 MAPK inhibited 
neutrophils. (c) Migration of PI3K and p38 MAPK inhibited 
neutrophils. Results are shown as mean   SEM (n   10) except for 
LTB4 and C5a containing experiments where n   8. *P   0.05 
compared with migration to IL-8 or LTB4. 
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Fig. 5 c demonstrates that alteration in PI3K/Akt was the
mechanism by which fMLP induces p38 MAPK–inhibited
neutrophils to migrate in greater numbers toward the inter-
mediary chemoattractants. First, inhibition of PI3K with
LY294002 eliminated p38-inhibited neutrophils from mi-
grating toward IL-8 (Fig. 5 c). To examine whether inhibi-
tion of p38 MAPK increased PI3K activity, we examined
Akt in the presence and absence of the p38 MAPK inhibi-
tors. Fig. 6 shows that phosphorylation of Akt in response to
fMLP and IL-8 peaks at 
 
 
 
1 min and returns to control by 5
min. However, when p38 MAPK inhibited neutrophils are
stimulated with both fMLP and IL-8, Akt phosphorylation
is high and remains high for at least 60 min (Fig. 6). In
additional experiments, p38 MAPK was activated by the
nonchemotactic end target molecule, LPS, a potent activator
of p38 MAPK (Haddad et al., 2001). LPS (10 ng/ml) pre-
treatment of neutrophils blocked migration to IL-8 (Fig. 7
a) in an identical fashion to fMLP. Inhibiting p38 MAPK
with SB203850 before LPS treatment reversed the LPS-
induced inhibition of migration to IL-8. However, the num-
ber of migrating neutrophils was not enhanced. Fig. 7 b
shows that AKT phosphorylation induced by IL-8 was abol-
ished in LPS-treated cells. p38 MAPK inhibition not only
restored phosphorylation of AKT in IL-8– and LPS-stimu-
lated cells, but once again the Akt phosphorylation was
stronger and more prolonged then the phosphorylation in-
duced by IL-8 alone (see Fig. 4 b for comparison). Clearly,
this is a common feature of numerous end target molecules.
Finally, to test how potent the reversal of the fMLP/IL-8
hierarchy with p38 MAPK inhibitors could be, p38-inhib-
ited neutrophils were placed into a well with fMLP, and IL-8
was placed into a distant well. Under these conditions,
p38 MAPK–treated neutrophils migrated out of the well
containing fMLP and toward the IL-8 gradient (Fig. 8). It
should be emphasized that IL-8 does not induce neutrophils
to migrate away from a local fMLP environment in the ab-
sence of p38 MAPK inhibition (Fig. 3 b). By contrast, when
p38 MAPK inhibited neutrophils were placed into an IL-8–
containing well, they failed to migrate efficiently toward
fMLP (Fig. 8).
 
IL-8 receptor number and function is not altered by 
p38 MAPK inhibition in opposing gradients
 
We examined several possibilities at the IL-8 receptor level
to explain the reversal and enhancement of leukocyte che-
motaxis away from end target chemoattractants and toward
intermediary chemoattractants when p38 MAPK is inhib-
ited. The first possibility was that fMLP and the p38 MAPK
inhibitor together altered IL-8 receptor number. FACS
 
®
 
analysis was used to determine if receptor internalization was
affected by p38 MAPK inhibition. Whereas IL-8 caused 78
Figure 6. Akt phosphorylation induced by simultaneous stimulation 
with 100 nM IL-8 and 100 nM fMLP in untreated cells and cells 
treated with 10  M SB203580. Data is shown as mean   SEM (n   4).
Figure 7. Effect of LPS on neutrophil chemotaxis and Akt 
phosphorylation induced by IL-8. (a) Neutrophils were pretreated 
for 1 h with 10 ng/ml LPS and then placed in wells adjacent to optimal 
concentrations of IL-8 (10.0 pmol). (b) Phosphorylation of Akt in 
LPS-treated neutrophils stimulated with IL-8   the p38 MAPK inhibitor 
SB203580. Results are shown as mean   SEM with a minimum 
n   9 for chemotaxis assay and n   3 for Akt phosphorylation. 
*P   0.05 compared with IL-8 alone. 
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and 72% of CXCR1 and CXCR2 internalization, respec-
tively, fMLP had minimal effects on CXCR1 or CXCR2
(
 
 
 
15%). When p38 MAPK–treated neutrophils were stim-
ulated with fMLP and IL-8, there was no alteration in the
pattern of CXCR1 and CXCR2 internalization compared
with fMLP and IL-8 stimulation of uninhibited cells (Table
II). Both perturbations induced 80–90% internalization of
CXCR1 and 70–75% of CXCR2 internalization.
Calcium flux was also unaltered by p38 MAPK inhibition.
Fig. 9 a shows that activation of CXCR1 and CXCR2 was
unaffected by p38 MAPK inhibition. fMLP stimulation in-
duced Ca
 
2
 
 
 
 influx of 60%. If IL-8 was then added to the
cells, only a 20–25% Ca
 
2
 
 
 
 influx was induced regardless of
whether p38 MAPK was inhibited. Similarly, Fig. 9 b shows
that IL-8 added first to neutrophils induced a 50–60% in-
crease in Ca
 
2
 
 
 
 influx. Subsequent addition of fMLP induced
a 50–60% Ca
 
2
 
 
 
 influx regardless of the presence of p38
MAPK inhibition. Clearly, Ca
 
2
 
 
 
 influx was not related to
the changes in chemotaxis.
Previous research has shown that IL-8 induces chemotaxis
primarily through CXCR1 and cell activation through
CXCR2 (Jones et al., 1996; Godaly et al., 2000). We used
blocking antibodies to both IL-8 receptors (CXCR1 and
CXCR2) to see if receptor function changed when cells were
treated with p38 MAPK inhibitors. IL-8–induced chemo-
taxis was entirely mediated by CXCR1 in our under agarose
assay (unpublished data). Next, a competing gradient con-
sisting of 1/100th optimal concentrations of fMLP (0.001
 
 
 
M) and optimal concentrations of IL-8 (1.0 
 
 
 
M) was pro-
duced. Adding anti-CXCR1 antibodies to p38 MAPK–
treated neutrophils reduced migration to IL-8 by 90% (Fig.
10). Adding anti-CXCR2 antibodies to p38 MAPK–treated
cells had no effect on migration to IL-8 (Fig. 10). These re-
sults suggest that chemotaxis to IL-8 was CXCR1 mediated
in p38 MAPK–treated neutrophils and that the pathways ac-
tivated by CXCR1 and CXCR2 are unchanged by p38
MAPK inhibition.
Figure 8. Migration of p38-MAPK inhibited neutrophils from a 
well containing 10.0 pmol IL-8 or 1.0 pmol fMLP to wells containing 
various concentrations of fMLP or IL-8. Results are shown as mean   
SEM (n   10). *P   0.05 compared with migration to IL-8.
Figure 9. Effect of p38 MAPK inhibition on receptor activation 
measured by calcium flux. Effect of p38 MAPK inhibition on 
calcium flux induced by 100 nM fMLP followed by 100 nM IL-8 (a) 
or 100 nM IL-8 followed by 100 nM fMLP (b).
 
Table II. 
 
CXCR1 and CXCR2 internalization in the presence of various stimuli
IL-8 receptor IL-8 alone fMLP alone IL-8 
 
 
 
 fMLP IL-8 
 
 
 
 fMLP 
 
 
 
 SB203580
 
%
 
CXCR1 78.3 
 
 
 
 1.7 14.9 
 
  13.8 82.8   5.7 90.8   1.5
CXCR2 72.0   9.6 12.5   4.8 74.3   1.2 69.6   1.7
Results are shown as the percentage of internalization   SEM. n   2 for IL-8   fMLP and IL-8   fMLP   SB203580. n   3 for IL-8 and fMLP. 98 The Journal of Cell Biology | Volume 159, Number 1, 2002
Downstream effectors
p38 MAPK and PI3K/Akt could activate the same adhesion
molecules for chemotaxis or could activate specific subunits
of the CD18 glycoprotein complex. Antibodies to LFA-1
(CD11a), Mac-1 (CD11b), and CD18 (the common unit
to LFA-1 and Mac-1) were used to block these adhesion
molecules. Anti-CD18 antibodies blocked migration to
both IL-8 and fMLP by  75% (Fig. 11 a). Anti–LFA-1 an-
tibodies had no impact on chemotaxis to fMLP, whereas
anti–Mac-1 antibodies blocked 60% of chemotaxis to
fMLP. Anti–LFA-1 antibodies blocked chemotaxis to IL-8
by 50%, but antibodies to Mac-1 had no significant impact
on chemotaxis to IL-8. In preliminary work, the p38 MAPK
inhibitors reduced Mac-1 up-regulation by 50–60% (un-
published data), suggesting downstream effects of these in-
hibitors on Mac-1 function.
We also looked at the impact of LFA-1 and Mac-1 inhibi-
tion in the fMLP/IL-8 hierarchy. We found that anti–LFA-1
had no significant impact on chemotaxis in this system,
consistent with the PI3K/Akt pathway being turned off by
fMLP upstream of LFA-1. Anti–Mac-1 again decreased mi-
gration by  50% (Fig. 11 b). Interestingly, anti–Mac-1 and
anti–LFA-1 in tandem completely blocked migration in the
p38 MAPK–inhibited fMLP/IL-8 hierarchy (unpublished
data), suggesting that both adhesion molecules become im-
portant for IL-8–induced migration when p38 MAPK is in-
hibited in opposing gradients of fMLP.
Discussion
During an infection, many chemoattractants are released
from various locations including the vascular endothelium,
interstitial cells (macrophages and mast cells), and the infec-
tious agent itself (Murdoch and Finn, 2000). These multiple
sources of chemoattractants result in a very complex milieu
of conflicting chemoattractant gradients that neutrophils
must navigate through in order to reach the site of infection.
One can envision numerous situations where neutrophils
would be faced with having to make decisions between mul-
tiple gradients of different chemokines. In fact, one could ar-
gue that this would occur anytime a neutrophil encounters
intermediary chemokines on the surface of endothelium, ad-
heres, and now must migrate away from this site and toward
a tissue source of end target chemoattractant (bacterial prod-
uct or complement fragment). Therefore, we hypothesized
that (a) endogenous-derived chemokines and end target bac-
terial chemoattractants would have different intracellular
signaling pathways, (b) that these pathways would function
in a hierarchical manner with end terminal pathways domi-
nating, and (c) that an active inhibition by the end target
signaling pathway of the intermediary chemoattractant-in-
duced intracellular signaling is an important mechanism in
the neutrophil decision-making process.
To study the decision-making (signaling) processes of
neutrophils in complex chemotactic fields, we used the un-
der agarose neutrophil migration assay first used by Nelson
et al. (1975) and more recently by Campbell et al. (1997)
and Foxman et al. (1997, 1999). This system allows for es-
tablishment of multiple simultaneous chemotactic fields.
There are advantages of this assay over the more widely used
Boyden chamber assay. Whereas the latter is used very effec-
tively for large scale screening of compounds, it is a unidi-
rectional fluid phase assay, which does not allow for the
effective study of bidirectional decision making by the neu-
trophils in response to multiple chemotactic agents. Al-
though the concentrations we used may appear larger than
what has been used in Boyden chambers, the concentrations
cannot be directly compared due to the more limited move-
ment of the chemokines in the agarose versus fluid in a Boy-
den chamber. Previously, investigators have used this assay
to report directional migration of neutrophils (Nelson et al.,
1975; Foxman et al., 1997, 1999). We have modified the as-
say so that we could quantify the number of cells that mi-
grated toward a particular chemotactic cue. This became ex-
tremely useful to report enhanced or decreased number of
migrating neutrophils in response to various manipulations
but required that we design the system in such a manner as
to be able to limit and count the number of migrating cells.
In this study, we report that end terminal chemoattractants
at various concentrations and in various scenarios domi-
nated over the chemotactic potential of intermediary che-
moattractants, consistent with the work of Campbell et
al., 1997, Foxman et al. (1997, 1999), and others (Knall et
al., 1997) using the same under agarose assay system. We ex-
tend the work to show that several of the end target mole-
cules induce chemotaxis via p38 MAPK, whereas in stark
contrast the intermediary chemoattractants use the PI3K/
Akt pathway in this system. More importantly, a hierarchy
between the two pathways exists in that the former has in-
hibitory impact upon the latter. This may be the underlying
problem in serious clinical situations like sepsis in which in-
creased levels of LPS, fMLP, or C5a in the circulation may
inhibit chemotaxis toward intermediary chemoattractants,
thereby preventing neutrophil infiltrations to sites of infec-
tions. Indeed, the inability of neutrophils to emigrate is a
well-described (Wagner and Roth, 1999) but unexplained
phenomenon in septic patients. In addition, neutrophils mi-
grated toward end target chemoattractants better when in-
termediary chemoattractants were present in an opposing
gradient, suggesting an amplifying loop, which, in the case
of fMLP, was at least in part due to increased fMLP receptor
number. Along the same lines of cross-talk, we report that
Figure 10. Effect of anti-CXCR1 and anti-CXCR2 antibodies on 
chemotaxis of p38 MAPK inhibited neutrophils in competing fMLP 
(0.01 pmol) and IL-8 (10.0 pmol) gradients. Results are shown as 
mean   SEM (n   5). *P   0.05 compared with no antibody.Hierarchy of neutrophil chemotaxis | Heit et al. 99
inhibition of the p38 MAPK pathway leads to an amplifica-
tion of the PI3K/Akt pathway in both magnitude and dura-
tion. The p38 MAPK inhibition results in neutrophil migra-
tion away from end-terminal chemoattractants and toward
intermediary chemoattractants in two- to fivefold greater
numbers. Finally, and most importantly, the enhanced
PI3K/Akt activation induced by p38 MAPK inhibitors is
causally related to the increase in neutrophil chemotaxis,
since inhibition of PI3K completely inhibited the enhanced
chemotaxis in response to intermediary chemokines.
There is some supportive data for individual end terminal
chemoattractants using p38 MAPK, whereas intermediary
chemoattractants use PI3K/Akt. Previous work has clearly
demonstrated that IL-8 activates PI3K/Akt, ERK, and p38
MAPK in primary human neutrophils (Knall et al., 1995;
Capodici et al., 1998). Inhibition of PI3K with wortmannin
inhibited ERK but not p38 MAPK activation, suggesting
that the activation of PI3K/Akt and ERK was distinct from
p38 MAPK activation (Knall et al., 1997). Moreover, p38
MAPK activation had no demonstrable role in the induction
of neutrophil chemotaxis in response to IL-8, whereas PI3K/
Akt was essential for IL-8–induced neutrophil chemotaxis
(Knall et al., 1997). The bacterial compound fMLP also ap-
pears to activate multiple intracellular signaling proteins in-
Figure 11. Role of LFA-1 and Mac-1 
in chemotactic responses. (a) Migration 
of neutrophils to fMLP and IL-8 when 
treated with blocking antibodies to 
CD11a (LFA-1), CD11b (Mac-1), and 
CD18 (common subunit of CD11a and 
CD11b). (b) Migration of neutrophils 
treated with blocking antibodies to 
CD11a and CD11b in competing 
gradients of fMLP and IL-8. Results are 
shown as mean   SEM (n   12). 
*P   0.05 compared with UT (isotype 
control).100 The Journal of Cell Biology | Volume 159, Number 1, 2002
cluding PI3K/Akt, ERK, and p38 MAPK (Zu et al., 1998;
Yasui and Komiyama, 2001). However, our data suggest
that activation of p38 MAPK but not PI3K/Akt blocked
fMLP-induced chemotaxis but had little impact on IL-8–
induced neutrophil chemotaxis. We observed for the first
time that when both pathways are activated simultaneously
p38 MAPK dominates by depressing PI3K/Akt activity.
Furthermore, p38 MAPK could interrupt and turn off pre-
viously activated PI3K/Akt in that when neutrophils were
placed in a well with IL-8 and fMLP was placed in a distal
well, the neutrophils would subsequently respond to fMLP,
despite having IL-8/PI3K/Akt activated first. This latter ob-
servation is likely critical to neutrophils terminating all activ-
ity in response to intermediary chemoattractants and re-
sponding to end target chemoattractants.
Our data reveals that cross-talk between p38 MAPK and
PI3K/Akt pathways is the inhibitory mechanism of action of
end target chemoattractants on intermediary chemoattrac-
tant responses. Cross-talk among different signaling path-
ways is not without precedent. In fact, a significant amount
of work has demonstrated that p38 MAPK and PI3K have
opposing effects on apoptosis in neutrophils, endothelium,
and other cells and that the PI3K/Akt pathway can inhibit
p38 MAPK pathway (Berra et al., 1998; Alvarado-Kristens-
son et al., 2002). Although to date no one to our knowledge
has shown that p38 MAPK negatively regulates PI3K/Akt,
one study has shown that p38 MAPK can associate with Akt
(Rane et al., 2001). In this study, we show that for chemo-
tactic stimuli in neutrophils, p38 MAPK appears to inhibit
PI3K. Moreover, when p38 MAPK is inhibited the effects of
PI3K/Akt are greatly unmasked as evidenced by both a very
substantial increase in Akt activity and a fivefold increase in
PI3K-dependent chemotaxis.
A second site of inhibition by fMLP/p38 MAPK on IL-
8/PI3K/Akt may be at the IL-8 receptor. Activation of the
fMLP receptor has been shown to cross-desensitize G pro-
tein activation stimulated by IL-8 (Richardson et al., 1995;
Ali et al., 1999). This process is mediated by receptor phos-
phorylation in which sites on the cytoplasmic end of the IL-8
receptors are phosphorylated by PKC. However, based on
data presented herein, we feel that neither phosphorylation
of the IL-8 receptor nor internalization is likely to be the
reason for neutrophils not responding to IL-8 in the pres-
ence of fMLP. First, fMLP had absolutely no effect on the
surface expression of either CXCR1 or CXCR2 in our sys-
tem. Second, placing neutrophils into a local environment
of IL-8 (Fig. 3 b) activated the IL-8 receptors and caused
rapid homologous desensitization and internalization (Fig.
4). Nevertheless, even after the IL-8 receptors were inter-
nalized and phosphorylated by local IL-8, neutrophils still
migrated toward fMLP placed in a distal well (in fact in
greater numbers than without IL-8 present). Clearly, inhi-
bition of the IL-8 pathway occurred down stream of the re-
ceptors and as our study suggests via p38 MAPK. More-
over, mutations at the phosphorylation sites on the IL-8
receptors do not inhibit responses to IL-8 stimulation (Rich-
ardson et al., 1998). As such, these authors predicted that
another mechanism downstream of the G proteins was in-
volved in maintaining the fMLP/IL-8 hierarchy. Our stud-
ies suggest that this mechanism is an inhibition of the PI3K
pathway by p38 MAPK. Mechanisms by which p38 MAPK
and PI3K/Akt differentially effect migration could include
relocalization of CD11/CD18 toward the leading edge of
neutrophils (preferentially toward end target chemoattrac-
tants), redistribution of CD11/CD18 into local microenvi-
ronments (e.g., lipid rafts) leading to improved chemotaxis
and/or increased affinity, and/or avidity in response to end
target chemoattractants but not intermediary chemokines.
Our preliminary work suggests that the p38 MAPK and
PI3K/Akt pathways may recruit different   subunits of the
CD18 glycoprotein complex and that in opposing gradients
Mac-1 seems to dominate over LFA-1. This would suggest
that the two   subunits of CD18 oppose rather than coop-
erate with each other. There is much controversy regarding
the relative importance of LFA-1 versus Mac-1 with studies
indicating a dominant role for either the former or the lat-
ter (Gao and Issekutz, 1996; Ding et al., 1999; Hogg and
Leitinger, 2001; Seo et al., 2001). Our observation that dif-
ferent chemoattractants may preferentially activate LFA-1
or Mac-1 separately would explain some of this contro-
versy. Although the prevailing view is that LFA-1 and Mac-1
function in a cooperative additive manner, this theory
does not explain the curious finding that for a particular
stimulus, LFA-1 deficiency in mice reduces neutrophil re-
cruitment, whereas Mac-1 deficiency actually increased
neutrophil recruitment (Ding et al., 1999), raising the pos-
sibility of some opposing effects of LFA-1 and Mac-1.
Materials and methods
Reagents
The p38 MAPK inhibitors SKF86002 and SB203580, the PI3K inhibitor
LY294002, and the chemoattractants C5a and LTB4 were purchased from
Calbiochem. Ficoll-Histopaque 1077, anti-CXCR1 antibodies, anti-CXCR2
antibodies, mouse IgG1 , Triton X-100, BSA, Tris HCl, Hepes, EGTA,
fMLP, IL-8,  -mercaptoethanol, bromophenol blue, orthovanadate, leu-
peptin, aprotinin, and the PI3K inhibitor wortmannin were purchased from
Sigma-Aldrich. HBSS, RPMI-1640 culture medium, and ultra pure agarose
were purchased from Life Technologies. FBS was purchased from Hy-
Clone Labs. Dextran (mol wt   250,000) was purchased from Spectrum.
35 mm   10 mm tissue culture dishes and FITC-conjugated goat anti–
mouse IgG were purchased from Becton Dickinson. Optilyse-B was pur-
chased from Immunotech. SDS was purchased from Bio-Rad Laboratories.
Highbond p  membrane, EPO developing kit, and Hyperfilm MP were
purchased from Amersham Biosciences. Rabbit anti–phospho-Akt (Ser
473) antibodies and HRP-conjugated anti–rabbit IgG antibodies were pur-
chased from Cell Signaling. Quantity One software was purchased from
Bio-Rad Laboratories.
Neutrophil isolation and preparation
Blood was collected from healthy human donors. Erythrocytes were re-
moved using dextran sedimentation (6% dextran/0.9% NaCl) followed by
two rounds of hypotonic lysis using ddH2O. Neutrophils were isolated
from the resulting cell suspension using Ficol-Histopaque density centrifu-
gation. The entire isolation was done at 4 C. Purified neutrophils were sus-
pended in HBSS at a concentration of 1.0   10
7 cells/ml and were kept on
ice until needed. Neutrophils were  95% viable and  97.5% pure as de-
termined by FACS
®.
Under agarose assay procedure
The under agarose assay was used as described previously (Nelson et al.,
1975; Foxman et al., 1999) with minor modification. Falcon 35 mm   10
mm culture dishes were filled with 3 ml of a 1.2% agarose solution con-
taining 50% H2CO3-buffered HBSS and 50% RPMI-1640 culture medium
with 20% heat-inactivated FCS. After the agarose solidified, three wells,
3.5 mm in diameter and 2.4 mm apart, were cut into a straight line in the
gel. The gels were allowed to equilibrate for 1 h in a 37 C/5% CO2 incuba-
tor. Unless otherwise noted, the center well was loaded with purified neu-Hierarchy of neutrophil chemotaxis | Heit et al. 101
trophils, and the outer wells were loaded with varying concentrations of
chemoattractant. Once loaded, the gels were incubated for 2 h in a 37 C/
5% CO2 incubator, which allowed sufficient time for neutrophils to mi-
grate the entire distance between the wells. Results were recorded using a
video camera attached to a ZEISS Axiovert 135 microscope.
For the dose response experiments, the two outer wells were loaded
with neutrophils, and the inner well was loaded with chemoattractant. The
maximum IL-8 concentration tested was 1.25  M, which was the concen-
tration of our stock solution.
p38 MAPK inhibitors were added to isolated neutrophils such that the
final inhibitor concentration was 30  M for SKF86002 and 10  M for
SB203580, which have been shown to be the optimal inhibitory concen-
tration without nonspecific effects (Zu et al., 1998). The concentrations of
PI3K inhibitors were 100 nM for wortmannin and 50  M for LY294002
(Niggli and Keller, 1997). All inhibitors were incubated with the neutro-
phils for 10 min. All neutrophils were stored on ice until needed.
To determine the effects of competing fMLP and IL-8 gradients, one
outer well was loaded with fMLP, the second outer well was loaded with
IL-8, and the central well was loaded with neutrophils. We examined
whether p38 MAPK was dominant over PI3K by adding p38 MAPK–inhib-
ited, PI3K-inhibited, or PI3K- and p38 MAPK–inhibited neutrophils to the
central well and IL-8 and fMLP into the two outer wells. To eliminate the
possibility of diffusion rates accounting for preferential migration, p38
MAPK–inhibited or untreated neutrophils were loaded into a well contain-
ing IL-8, and fMLP was placed in an adjacent well (or vice versa).
To test the role of the two IL-8 receptors (CXCR1 and CXCR2) in the
fMLP/IL-8 hierarchy, we treated neutrophils with either 2.5  g/ml anti-
CXCR1 or 10  g/ml anti-CXCR2 antibodies and loaded these neutrophils
into the central well of a gel containing IL-8 and fMLP in its outer wells.
Video analysis
The under agarose assay allows quantification of both random migration
(chemokinesis) and directional migration (chemotaxis). To determine if the
migration we observed was directional, two target areas were analyzed.
Target A was a segment 500  m   2,300  m between the neutrophil con-
taining well and the chemoattractant containing well. Target B was of the
same size as the first zone but extended from the neutrophil well to a point
directly opposite the chemoattractant containing well (Fig. 1 a). The num-
ber of chemotaxing cells was determined by subtracting the number of mi-
grating cells in target B from the number of migrating cells in area A.
IL-8 neutrophil receptor analysis using FACS
®
Whole blood was diluted 1/10 with HBSS. Blood was stimulated using
fMLP or IL-8 (1–100 nM) for 20 min at 37 C. Control tubes (cells alone) re-
ceived no chemoattractant but were placed at 37 C for 20 min. Anti-
CXCR1 or anti-CXCR2 primary antibody was added to experimental tubes
at 2.5 and 10  g/ml, respectively, and isotype IgG2a antibody was added
to control tubes. All antibodies were incubated at 37 C for 15 min. Un-
treated and treated controls were used to ensure stimulation did not induce
autofluorescence and nonspecific binding. After labeling, cells were
washed and then lysed with Optilyze B solution for 10 min. Cells were
washed again and incubated with FITC-labeled secondary antibody. After
a 15 min, incubation cells were washed and resuspended in HBSS to a
concentration of 1.0   10
6 cells/ml.
To test the effects of the p38 MAPK inhibitor, SB203580, on receptor in-
ternalization, neutrophils were treated with 10  M SB203580 and then la-
beled using anti-CXCR1 or anti-CXCR2 antibodies as described previously.
These cells were stimulated with 0.0001–0.1  M fMLP and incubated for
20 min at 37 C. Fluorescent intensity was analyzed using flow cytometry
gating on the neutrophil population.
Calcium flux
Isolated human neutrophils at a concentration of 10 million cells/ml were
either left untreated or inhibited with the p38 MAPK inhibitor SB203580
for 1 h at 37 C. These cells were labeled with 4  M fluo-3 dye at 37 C for
30 min with occasional agitation. Cells were washed twice with Hepes
buffer with 1 mM calcium (145 mM NaCl, 5 mM KCl, 1 mM MgCl, 10 mM
Hepes, and 10 mM glucose) and centrifuged at 1,300 rpm for 6 min. The
neutrophils were diluted to one million cells per ml in Hepes buffer and pi-
petted into 4-mL cuvettes in PerkinElmer fluorescence spectrometer 650–
10S with an excitation wavelength of 480 nm and emission recorded at
530 nm. Neutrophils were initially stimulated with 100 nM IL-8 or fMLP.
Once the calcium levels stabilized, the cells were stimulated a second
time with an additional 100 nM IL-8 or fMLP. Calcium flux was measured
as the percentage of total calcium (fmax). fmax was determined by treating
fluo-3–labeled cells with Triton X-100.
Akt blotting
p38 MAPK inhibited and uninhibited neutrophils at a concentration of 4.0  
10
7 cells/ml were treated with fMLP and/or IL-8 such that the final con-
centration of either chemoattractant was 100 nM. Aliquots of these cell
suspensions were removed at various time points and added to an equal
volume of boiling 2  Laemmli buffer (125 mM Tris HCl, pH 6.8, 8% SDS,
10%   mercapto ethanol, 17% glycerol, 6.65% bromophenol blue, 5 mM
orthovanadate, 10  g/ml leupeptin, and 10  g/ml aprotinin). Samples
were then electrophoresed on an 8% SDS–polyacrylamide gel and trans-
ferred to a highbond p  membrane. Blots were immunoblotted using anti–
phospho-Akt antibody in TBS-tween with 2% BSA. The blots were then
stripped and reprobed with anti-Akt antibodies to show that all lanes were
loaded equally. Both blots were visualized on radiography film using a
secondary antibody conjugated to HRP and an EPO chemiluminescence
kit. Densitometry was performed using Quantity One software.
Statistics
All data are expressed as the arithmetic mean   SEM. Data was compared
using a single sample t test unless otherwise noted. Values of P   0.05
were considered to be statistically significant.
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